SOPHiA GENETICS SA SOPH
NASDAQ · United States · Technology Services
$8.38+0.08 (+0.96%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
SOPHiA GENETICS is back in focus as analysts reset their central price views, with fair value moving from US$9.00 to US$9.75. Recent research linking the company’s role in data driven oncology and rare disease diagnostics with Q2 results and higher guidance has supported price targets in a US$9 to US$12 range, while still flagging execution and valuation risk. Read on to see how these shifting targets feed into the broader SOPHiA GENETICS story and how you can track the narrative from...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.